GBIO insider trading
HealthcareGeneration Bio Co.: insider trade history from SEC Form 4 filings.
About Generation Bio Co.
Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise mechanism of target engagement could unlock a series of high-value historically undruggable disease-driving genes in autoimmunity. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Company website: generationbio.com
GBIO insider activity at a glance
FilingIQ tracks 488 insider transactions for GBIO in filings since Jun 16, 2020. The most recent transaction is dated Feb 9, 2026.
Across the full history, 25 open-market purchases
and 167 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on GBIO insider trades is 59.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest GBIO Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for GBIO?
- FilingIQ tracks 488 Form 4 insider transactions for GBIO (Generation Bio Co.), covering filings from Jun 16, 2020 onwards. 0 of those are dated within the last 90 days.
- Are GBIO insiders net buyers or net sellers?
- Across the full Form 4 history for GBIO, 25 transactions (5%) were open-market purchases and 167 (34%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does GBIO insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is GBIO in?
- Generation Bio Co. (GBIO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $35.98M.
Methodology & sources
Every GBIO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.